RenovoRx, Inc.

RNXT · Nasdaq · SIC 2834: Pharmaceutical Preparations
87
SEC Filings

Business Summary

Government Regulation for more information. We may be required to suspend or discontinue clinical trials due to unexpected side effects or other safety risks that could preclude approval of our product candidates. Our clinical trials may be suspended at any time for a number of reasons. For example, we may voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable risk to the clinical trial patients. In addition, the FDA or other regulatory a...

Next Earnings

Q2 FY2026 — expected 2026-08-17

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionRNXTdiscussed_in_filing Cybersecurity
topic_mentionRNXTdiscussed_in_filing Cybersecurity
topic_mentionRNXTdiscussed_in_filing Regulation
topic_mentionRNXTdiscussed_in_filing Sovereign & Government
topic_mentionRNXTdiscussed_in_filing Regulation
topic_mentionRNXTdiscussed_in_filing Sovereign & Government

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-302025-12-310001193125-26-131928EDGAR80K words
2025-04-012024-12-310001641172-25-001932EDGAR—
2024-04-012023-12-310001493152-24-012357EDGAR—
2023-03-312022-12-310001493152-23-010332EDGAR—
2022-03-302021-12-310001493152-22-008080EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-132025-09-300001493152-25-022304EDGAR28K words
2025-08-142025-06-300001641172-25-024020EDGAR—
2025-05-152025-03-310001641172-25-010935EDGAR—
2024-11-132024-09-300001493152-24-045137EDGAR—
2024-08-132024-06-300001493152-24-031675EDGAR—
2024-05-102024-03-310001493152-24-018704EDGAR—
2023-11-132023-09-300001493152-23-040598EDGAR—
2023-08-162023-06-300001493152-23-029125EDGAR—
2023-05-122023-03-310001493152-23-016648EDGAR—
2022-11-142022-09-300001493152-22-031491EDGAR—
2022-08-122022-06-300001493152-22-022384EDGAR—
2022-05-132022-03-310001493152-22-013294EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-300001493152-26-013653EDGAR4K words
2026-03-270001493152-26-013080EDGAR—
2026-03-230001493152-26-012058EDGAR—
2026-02-060001493152-26-005437EDGAR—
2026-01-020001493152-26-000113EDGAR—
2025-11-140001493152-25-023604EDGAR—
2025-11-130001493152-25-022325EDGAR—
2025-08-140001641172-25-024147EDGAR—
2025-06-250001641172-25-016512EDGAR—
2025-05-150001641172-25-010895EDGAR—

87 total filings indexed. 60 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001574094
TickerRNXT
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: ea1b50779fbe3b7f0aae206b9f9a7e68a0c674ad9c28d64674ff880d6e6fac13
parent: 54f3cfc520d422deef455ae172f57c421bce953f026eab8153cac99409283f8b
content hash: 0a2f93e64d58896035a26f17e31312c332edc9befeb9b39b97096403d4d89d86
signed: 2026-04-13T04:47:14.384Z
sources: 17 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf